UTA’s Integrated Cancer Research Strives to Improve Patient Outcomes, Experience
By UT Arlington University Communications
Posted on January 25, 2017, January 25, 2017

Improve Patient Outcomes

The University of Texas at Arlington is becoming a major cancer research institute, receiving more than $6 million dollars in new grants in 2016 to strengthen its integrated cancer research program and improve outcomes across the complete spectrum of the patient experience.

"UTA's scientific expertise across basic cancer research, identification and diagnostics and non-invasive, mid-term, invasive and post-operative therapies is accelerating dramatically in order to enable substantial impact on health in Texas," UTA President Vistasp Karbhari said.

"By assembling a world-class team that works together we hope not only to make transformative advances in key areas related to cancer, but also to provide the highest level of educational and research experiences to our students, in keeping with our Strategic Plan theme of Health and the Human Condition."

Following a strong recruiting effort, UTA's cancer team now includes more than 25 faculty from across the Colleges of Science, Engineering and Nursing and Health Innovation, all focused on developing new ways to find and treat cancer.

"In 2016, UTA was named in the elite group of R1: Doctoral Universities - Highest Research Activity by the Carnegie Classification of Institutions of Higher Education, joining a distinguished group of 115 institutions including Harvard, MIT and Johns Hopkins," added Duane Dimos, UTA's vice president for research. "We also broke ground on a new $125 million Science and Engineering Innovation and Research building, which will be the University's signature research facility for multidisciplinary life and health science teaching and research. It is our moment to move forward in cancer."

UTA's cancer research is also moving out of the lab and into the commercial sector, with several companies formed around the University in key areas like immunotherapy or the development of novel chemical compounds to attack cancer.

"We are positioning UTA as the innovation hub around cancer for the North Texas region," Dr. Dimos said.

Support Quality Education
Education, News, UT Arlington